CClinicalTrials.gg
Status unknownNCT04549272Updated Apr 11, 2022

Assessment of Early Vascular Damage With Advanced Neuroimaging in Patient With Patent Foramen Ovale

An observational study in Patent Foramen Ovale, sponsored by Neuromed IRCCS. Status unknown. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Neuromed IRCCS · Observational

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Not yet recruiting — may be out of date.
Study type
Observational
Model
Case-only
Time perspective
Cross-sectional
Enrollment
100
Ages
18 Years to 65 Years
Sex
All
01

Study summary

Patent foramen ovale arises from the incomplete postnatal fusion of the septum primum and secundum and can cause paradoxical embolism in adults. In case of cerebral ischemic stroke, the correlation with the patent foramen ovale is based on probabilistic approach. For this reason, continuous research is indispensable, especially according to new approaches, to offer tools capable of guiding in case of adverse event with greater certainty and even better to prevent it. Thus, this study aims to: 1) evaluate the microstructural brain damage through advanced MRI analysis in patients with patent foramen ovale; 2) evaluate how much the degree of the shunt can affect brain damage. In order to do this, this study aims to evaluate advanced brain imaging in a cohort of patients with patent foramen ovale to identify the development of early vascular damage.

02

Conditions studied

  • Patent Foramen Ovale

Browse trials for

Keywords

  • Magnetic Resonance Imaging
  • Vascular Cognitive Impairment
03

In context

Foramen Ovale, Patent

134 studies on the registry are indexed under Foramen Ovale, Patent; 46 are open to participants now.

This study's planned enrollment of 100 is below the median of 226 across 57 observational studies indexed under Foramen Ovale, Patent.

Browse Foramen Ovale, Patent studies →

Lead sponsor

Neuromed IRCCS is the lead sponsor of 76 studies on the registry; 23 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects will be selected from patients attending the Department of AngioCardioNeurology of the IRCCS Neuromed, accordingly to the following inclusion/exclusion criteria. Approximately 100 subjects of both genders will be included in the study.

Inclusion criteria

  • age ≥ 18 and ≤ 65 years
  • patients with patent foramen ovale
  • written informed consent

Exclusion criteria

Exclusion Criteria:

  • previous IMA, stroke or TIA
  • arrhythmia or severe cardiac disease
  • hypertension, diabetes or renal disease
  • psychiatric disease
  • neurological or neurodegenerative disease
  • dementia
  • assumption of drugs known to interfere with cognitive function
  • inability to be subjected MRI analysis
  • participation to other clinical trial, ongoing or terminated less than one month before enrolment in this study.
05

Study design

Observational model
Case-only
Time perspective
Cross-sectional
Enrollment
100 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Patients with Patent Foramen Ovale

    Other: No interventions

Interventions

  • OtherNo interventions

    No interventions - observational study

06

What researchers measure

Primary outcomes

  1. Measurement of percentage change in diffusion parameters of the white matter

    Fiber tracking by DTI MRI

    Time frame: At Enrollment

Secondary outcomes

  1. Quantification of the degree of shunt of the patent foramen ovale

    Echography

    Time frame: At Enrollment

  2. Detection of cognitive decline by decrease of MoCA score

    Cognitive tests

    Time frame: At Enrollment

  3. Detection of a non-invasive retinal screening

    Digital ophthalmoscope

    Time frame: At Enrollment

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04549272
Lead sponsor
Neuromed IRCCS
Responsible party
Giuseppe Lembo (Full Professor, MD, PhD, Neuromed IRCCS) — Principal investigator
First posted
Sep 16, 2020
Start date
Oct 2022 (estimated)
Primary completion
Oct 2023 (estimated)
Completion
Oct 2023 (estimated)
Last update
Apr 11, 2022

Study contacts

Giuseppe Lembo, MD, PhD
Contact
lembo@neuromed.it
+390865915225

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion